



Tehran University of Medical  
Sciences Publication  
<http://tums.ac.ir>

## Iran J Parasitol

Open access Journal at  
<http://ijpa.tums.ac.ir>



Iranian Society of Parasitology  
<http://isp.tums.ac.ir>

### Case Report

## An Atypical Presentation of Disseminated Mucocutaneous Leishmaniasis Caused by *Leishmania major* In Iran

Pedram NORMOHAMADPUR, \*Forugh GHAEDI

Razi Hospital, Vahdat Eslami Street, Tehran, Iran

<p>Received 10 May 2017 Accepted 25 Sep 2017</p>	<p><b>Abstract</b> Although leishmaniasis is an endemic disease in Iran the mucosal involvement is rare. Mucocutaneous leishmaniasis (MCL) mainly caused by <i>Leishmanial braziliensis</i> infection, reported with other <i>Leishmania</i> species such as <i>L. major</i>. Herein a 78 yr old man with MCL from Iran is presented who referred to Razi Hospital Dermatology Clinic, Tehran, Iran, for multiple ulcerative lesions on mid face skin, mucosa of upper lip and anterior fossa of nose, dorsal aspect of the hands and the posterior aspect of heels. Skin biopsy revealed necrotizing and granulomatous tissue pattern that suggested infection pathogenesis but the smear for leishmaniasis, <i>Mycobacterium</i> spp, and fungal elements was negative at first. In order to a positive PPD test, he was treated by anti-tuberculosis treatment. A month after starting drugs for tuberculosis, the prepared microscopical smears were positive for Leishman bodies this time. The skin biopsy revealed amastigote forms of <i>Leishmania</i> sp. and the PCR assay on specimens of lesions proved <i>L. major</i> as the principal pathogenic agent. There was good response to systemic treatment with meglumine antimoniate (Glucantime®) 3 gr per day until one week followed by 4.5 gr per day for another week. We forced to discontinue of drug because of cardiac toxicity at the end of 2<sup>nd</sup> wk of treatment.</p>
<p><b>Keywords:</b> Leishmaniasis, Mucocutaneous, <i>Leishmania major</i></p>	
<p><b>*Correspondence Email:</b> <a href="mailto:f_ghaedi@edc.mui.ac.ir">f_ghaedi@edc.mui.ac.ir</a></p>	

### Introduction

Leishmaniasis is a worldwide protozoal disease and is endemic in Iran. There are several clinical features but cutaneous and visceral leishmaniasis are the most common type of involvement in Iran as the same as the world (1,2).

An average annual incidence 32 cases per 100000 inhabitants for cutaneous leishmaniasis was reported in Iran based on the cross-sectional study from 1983 to 2012 (3).

The main etiological agents for cutaneous leishmaniasis are *L. major* and it is endemic in

17 out of 31 provinces of Iran, including Ilam that our patient is from there (4).

Cutaneous leishmaniasis caused by *L. major* is zoonotic and desert rodents (gerbils) are principal reservoir hosts of disease in various parts of Iran (5).

MCL is a destructive disease that affects the mucous membranes of the mouth, nose, pharynx, and larynx. Mucosal involvement is rare in Iran as well as its low prevalence in the world (6).

This type of leishmaniasis mainly caused by *L. braziliensis* infection, although it has occasionally been reported with other *Leishmania* species like *L. major* (7-9), *L. tropica* (7, 10), *L. Infantum* (11,12).

## Case report

A 78 yr old man from a rural area at the western of Iran referred to Razi Hospital Dermatology Clinic, Tehran for multiple ulcerative and exudative lesions on mid face, dorsal aspect of hands and the posterior aspect of heels (Fig. 1, 2).

Informed consent was taken from the patient.



Fig. 1: Mucocutaneous lesions on the face

Lesions initiated three years before with papules on the dorsal aspect of the hands then progressively enlarged above the upper lip,

anterior portion of the nasal fossa, above the eyebrows and heels and became ulcerative.

During the past 3 yr, the lesions of hands were so developed that destroyed the tendons and soft tissue of fifth finger in the right hand so led to amputation of this finger. There was no history of comorbid condition, drug consumption, systemic symptoms, weight loss, fever, lymphadenopathy, hepatosplenomegaly or any signs of systemic involvement in physical examination and laboratory survey.



Fig. 2: Ulcerative lesion on the right hand

Multiple treatments in order to some heterogenic diagnosis such as pyoderma gangrenosum, sarcoidosis, and leishmaniasis were tried without any improvement in lesions.

In Razi Hospital Dermatology Clinic, initial Skin biopsy revealed necrotizing and palisading granulomatous tissue pattern that suggested infections etiology but the smear of lesions for fungal and mycobacteria and *Leishmania* was negative. In order to result of PPD test with 27 mm induration, anti-tuberculosis treatment including isoniazid, rifampin, ethambutol, and pyrazinamide was started.

A month after initiating drugs for tuberculosis, the smear of leishmaniasis repeated that was positive this time, the second biopsy revealed pseudoepitheliomatous hyperplasia and infiltration of the dermis by mixed inflammatory cells and Leishman bodies compatible with leishmaniasis.

Restriction fragment length polymorphism (RFLP) PCR was carried out on DNA extraction was carried out with QIAGEN Kit according to the manufacturer's instruction using two primers, LITSR (5-GTG CAG GAT CAT TTT CCG ATG) and L5.8s: 5-TGA TAC CAC TTA TCG CAC TT was designed

for LTS1-PCR and cutting with HaeIII enzyme. Positive controls containing DNA of *L. major*, *L. tropica* and a negative control containing distilled water were included. The PCR-RFLP on specimens of lesions proved *L. major* as the pathogenic agent (13, 14)(Fig. 3).




Fig. 3: The PCR-RFLP on specimens of lesions

From the left side, the 2 bands show *L. major*, the second 2 bands show *L. tropica*, the 5<sup>th</sup> one is the specimens of lesions that compatibles with *L. major* and the last one show *L. tropica*.

Treatment initiated with 3 gr per day of meglumine antimoniate (Glucantime®) until 1

wk followed by 4.5 gr per day for another week, in spite of good response to meglumine antimoniate after 2 wk of treatment we forced to discontinue of drug because of cardiac toxicity (Figs. 4, 5).

The patient was informed about publishing his figures whit covering eyes.



Fig.4: Significant treatment of lesion by meglumine antimoniate



Fig. 5: Significant treatment of lesion by meglumine antimoniate

## Discussion

Although leishmaniasis is an endemic disease in Iran, the mucosal involvement is a rare condition. Furthermore, there are a few reports of mucosal leishmaniasis with *L. major* in Iran (7-9, 15).

Shirian et al evaluated clinical features of 11 Iranian patients with mucosal leishmaniasis (15). They demonstrated pathogenesis of mucosal involvement in leishmaniasis was different in order to the causative species. *L. infantum* and *L. tropica* induced primary mucosal lesions without former skin involvement but *L. major* was the causative agent of secondary (metastatic) mucosal leishmaniasis. Lymphatic or hematogenous dissemination of parasites via the affected skin may cause localization of the disease in the nasal, oral, and pharyngeal mucosa. Compatible with Shirian et al observations, in our case, the primary lesions were cutaneous and the mucosal lesions were developed from distribution of skin lesions.

Furthermore Shirian et al observed *L. major* was the most causative agent in the lesions of nose, gingival, hard and soft palates and *L. tropica* was detected from the gingival and lower lip lesions. *L. infantum* was isolated from two cases with sever involvement of epiglottis and laryngeal mucosa (15). In our case, the mucosa membrane of the nose and upper lip was involved, compatible with the pathogenic manner of *L. major* that Shirian et al observed (15).

In the background of an immunosuppression such as HIV infection, renal transplantation, and drug-induced immunosuppression, disseminated cutaneous lesion with *L. major* is probably (16,17). However, in our patient there was no evidence for immunosuppression. Four cases of disseminated cutaneous leishmaniasis with *L. major* were reported (18). As none of them had no immunosuppressive state that explained the extent of lesions, they indicated the genomic charac-

teristics of *Leishmania* parasites may be a significant role in *Leishmania* pathogenicity. Because of increasing trips and migration between endemic and non-endemic areas, in recent years, change in distribution of the parasite is occurred (19) and it is possible to produce new hybrid of *Leishmania* with different pathogenicity (20, 21).

DNA based molecular methods suggest for true identification of the causative agent of leishmaniasis for appropriate treatment, control, and prevention. Our patient was from Ilam Province located in the west of Iran near the Iraq border and their theory about changing in the pathogenicity of *L. major* is possible.

Apart of the rare manifestation of this patient as a disseminated cutaneous and mucosal form of leishmaniasis with *L. major*, an interesting point of this case is possible coinfection with *Mycobacterium tuberculosis* in order to a strong positive PPD test and granulomatous pattern of skin biopsy. Although we could not succeed to detect acid-fast basil from the lesion but the parasite of *Leishmania* was detected after treatment of tuberculosis, therefore, secondary infections can interfere with diagnosis of leishmaniasis so in infected cases, it is necessary to return evaluate leishmaniasis after a period of appropriate antibiotic therapy if a strong suspicion to leishmaniasis is propounded.

## Acknowledgements

The authors thank Prof. Mehdi Mohebali, Dr. Homa Hajjaran, Dr. Behnaz Akhondi, Miss. Zahra Kakoei and Mrs. Zahra Shafeghat, from Leishmaniasis Laboratory, School of Public Health of Tehran University of Medical Sciences for their assistance in performing laboratory assays.

## Conflict of interest

The authors declare that there is no conflict of interest.

## References

1. Diseases Management Center, Ministry of Health, Treatment and Medical Education of Iran (2002–2010) Annual Communicable Diseases Report.
2. Mohebbali M. Visceral leishmaniasis in Iran: review of the epidemiological and clinical features. Iran J Parasitol. 2013; 8(3):348-58.
3. Shirzadi MR, Esfahania SB, Mohebbali M et al. Epidemiological status of leishmaniasis in the Islamic Republic of Iran, 1983–2012. East Mediterr Health J. 2015; 21(10):736-42.
4. Akhavan A, Yaghoobi-Ershadi M, Mirhendi H et al. Molecular epizootiology of rodent leishmaniasis in a hyperendemic area of Iran. Iran J Public Health. 2010; 39(1):1-7.
5. Mohebbali M, Javadian E, Yaghoobi-Ershadi MR et al. Characterization of *Leishmania* infection in rodents from endemic areas of the Islamic Republic of Iran. East Mediterr Health J. 2004; 10(4-5):591-9.
6. Daneshbod Y, Oryan A, Davarmanesh M et al. Clinical, histopathologic, and cytologic diagnosis of mucosal leishmaniasis and literature review. Arch Pathol Lab Med. 2011; 135(4):478-82.
7. Mortazavi H, Mohebbali M, Taslimi Y et al. Hoarseness as the Presenting Symptom of Visceral Leishmaniasis with Muco-Cutaneous Lesions: A Case Report. Iran J Parasitol. 2015; 10(2):296-300.
8. Shirian S, Oryan A, Hatam GR, Daneshbod Y. Mixed mucosal leishmaniasis infection caused by *Leishmania tropica* and *Leishmania major*. J Clin Microbiol. 2012; 50(11):3805-8.
9. Alborzi A, Pouladfar GR, Ghadimi Moghadam A et al. First molecular-based detection of mucocutaneous leishmaniasis caused by *Leishmania major* in Iran. J Infect Dev Ctries. 2013; 7(5):413-6.
10. Morsy TA, Khalil NM, Salama MM et al. Mucosal leishmaniasis caused by *Leishmania tropica* in Saudi Arabia. J Egypt Soc Parasitol. 1995; 25(1):73-9.
11. Casolari C, Guaraldi G, Pecorari M et al. A rare case of localized mucosal leishmaniasis due to *Leishmania infantum* in an immunocompetent Italian host. Eur J Epidemiol. 2005; 20(6):559-61.
12. Cobo F, Aliaga L, Talavera P, Concha A. The histological spectrum of non-granulomatous localized mucosal leishmaniasis caused by *Leishmania infantum*. Ann Trop Med Parasitol. 2007; 101(8):689-94.
13. Kazemi-Rad E, Mohebbali M, Hajjaran H et al. Diagnosis and characterization of *Leishmania* species in Giemsa-stained slides by PCR-RFLP. Iran J Public Health. 2008; 37:54–60.
14. Mohebbali M, Darabi H, Hajjaran H et al. Molecular and parasitological study of cutaneous leishmaniasis in Bushehr province, southwest of the Islamic Republic of Iran: a cross-sectional study during 2009–2012. J Parasit Dis. 2015; 39(3):371-6.
15. Shirian S, Oryan A, Hatam GR, Daneshbod Y. Three *Leishmania*/L. species--*L. infantum*, *L. major*, *L. tropica*--as causative agents of mucosal leishmaniasis in Iran. Pathog Glob Health. 2013; 107(5):267-72.
16. Venencie PY, Bourée P, Hiesse C et al. Disseminated cutaneous leishmaniasis in a case of an immunodepressed woman. Ann Dermatol Venereol. 1993; 120(6-7):461-3.
17. Moravvej H, Barzegar M, Nasiri S et al. Cutaneous leishmaniasis with unusual clinical and histological presentation: report of four cases. Acta Med Iran. 2013; 51(4):274-8.
18. Hajjaran H, Mohebbali M, Akhavan AA et al. Unusual presentation of disseminated cutaneous leishmaniasis due to *Leishmania major*: case reports of four Iranian patients. Asian Pac J Trop Med. 2013; 6(4):333-6.
19. Kassiri H, Sharifinia N, Jalilian M et al. Epidemiological aspects of cutaneous leishmaniasis in Ilam province, west of Iran (2000-2007). Asian Pac J Trop Dis. 2012; 2(Suppl 1): S382-S386.
20. Shiee MR, Hajjaran H, Mohebbali M et al. A molecular and parasitological survey of cutaneous leishmaniasis patients from historical city of Kashan in Isfahan province, center of Iran. Asian Pac J Trop Dis. 2012; 2(6):421-425.
21. Ravel C, Cortes S, Pratlong F et al. First report of genetic hybrids between two very divergent *Leishmania* species: *Leishmania infantum* and *Leishmania major*. Int J Parasitol. 2006; 36(13):1383-8.